Davide De Marco

Davide De Marco

Auto-generated profile, based on publicly available information

Davide De Marco

Division of Gastroenterology and Hepatology, McGill University Health Centre , Montreal, Québec, H3H 1V6

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2023 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
DMDavide De Marco
Davide De Marco
KPKarol Pencina
Karol Pencina
MPMichael Pencina
Michael Pencina
LDLine Dufresne
Line Dufresne
GTGeorge Thanassoulis
George Thanassoulis
ASAllan D. Sniderman
Allan D. Sniderman

16 November 2022 in ACG Case Reports Journal
Verified
Journal Article
Open access
DMDavide De Marco
Davide De Marco
TBTalat Bessissow
Talat Bessissow
VMVictoria Marcus
Victoria Marcus
ABAmine Benmassaoud
Amine Benmassaoud
Vedolizumab, which is approved for the treatment of ulcerative colitis, has been associated with drug-induced liver injury because of an unclear mechanism. We describe the case of a 29-year-old man who presented with abnormal liver enzymes and peripheral hypereosinophilia after vedolizumab initiation. A complete workup for causes of hepatitis and hypereosinophilia was negative, and liver biopsy showed signs compatible with drug-induced liver injury. After the withdrawal of vedolizumab, the patient's eosinophil count and liver enzymes normalized. As vedolizumab becomes more prominent, it is important to understand the potential side-effect profile of vedolizumab.

2 April 2025 in Journal of the Canadian Association of Gastroenterology
Verified
Journal Article
Open access
DMDavide De Marco
Davide De Marco
VHValerie Heron
Valerie Heron
ABAlain Bitton
Alain Bitton
TBTalat Bessissow
Talat Bessissow
PLPeter Lakatos
Peter Lakatos
WAWaqqas Afif
Waqqas Afif
Background/Aims: Among Crohn’s disease patients with loss of response or non-response to ustekinumab (UST), there remains no clear strategy for dose escalation. Moreover, clinical associations and the role of therapeutic drug monitoring (TDM) are poorly understood. This study assessed response to escalation of UST therapy via increased dosing frequency or re-induction, as well as assessed associations of response. Methods: A single-centre retrospective cohort study was performed. Adults who underwent dose escalation to every 4 weeks or reinduction of UST were included. The primary outcome was clinical and biochemical remission which was defined as a Harvey Bradshaw Index (HBI) of <5 and a C-reactive protein (CRP) level within the normal limit or a Fecal Calprotectin (FCP) level <250 ug/g. Partial response to treatment was defined as a 50% decrease from baseline HBI, CRP, or FCP. Results: Thirty-nine patients were included. Clinical outcomes were assessed at a median of 17 weeks (IQR 12-21). Clinical and biochemical remission was achieved in 30.8% of patients (n = 12). Remission was found to be more likely among patients with lower baseline HBI (5.2 vs 9.0 P = .044) and younger patients (29.8 years vs 37.7 P = .046). No association was observed between baseline TDM values in the remission vs the non-remission group (3.32 ug/mL vs 2.91 ug/mL p=0.77). No severe adverse events were recorded. Conclusion: UST dose escalation, in the form of reinduction or increased frequency to every 4 weeks may be effective among patients with loss of response or partial response, though predictors of response and strategy of escalation remain unclear.

18 February 2026 in Journal of the Canadian Association of Gastroenterology
Verified
Journal Article
Open access
DMDavide De Marco
Davide De Marco
KMKevin McHugh
Kevin McHugh
SPSophie Plamondon
Sophie Plamondon
LRLouis-Charles Rioux
Louis-Charles Rioux
ASA Hillary Steinhart
A Hillary Steinhart
WAWaqqas Afif
Waqqas Afif
Background: There is limited evidence to support optimal concentrations for therapeutic drug monitoring in patients with Crohn’s disease (CD) who experience a loss of response (LOR) to tumour necrosis factor antagonists. This study aimed to determine the threshold trough adalimumab concentration beyond which patients with LOR are unable to recapture a response after dose escalation. Methods: Enrolled patients had responded to adalimumab therapy after ≥16 weeks and subsequently experienced a secondary LOR, defined as a C-reactive protein (CRP) level ≥5 mg/L and/or a fecal calprotectin (FC) level ≥250 µg/g. Dosing was escalated from biweekly to weekly. Patients were then assessed for 12 weeks to determine their ability to recapture a response, defined as a CRP response (≥50% CRP decrease and/or CRP <5 mg/L) and/or FC response (≥50% FC decrease and/or FC <150 µg/g). The relationship between baseline trough concentration and non-recapture of biochemical response was evaluated using logistic regression. Results: Of 97 enrolled patients, 49 (50.5%) did not recapture a response to adalimumab after dose escalation. Baseline trough concentration was not associated with non-recapture of biochemical response (odds ratio, 0.98; 95% CI: 0.91-1.06; P = .626). There was no threshold trough concentration identified that was predictive of non-recapture of biochemical response. No new adalimumab safety signals were identified. Conclusions: No association was observed between trough adalimumab concentration and non-recapture of biochemical response after dose escalation for secondary LOR in CD. The threshold concentration above which dose escalation is ineffective remains unclear. ClinicalTrials.gov identifier: NCT02896985.